<DOC>
	<DOCNO>NCT00001565</DOCNO>
	<brief_summary>This pharmacokinetic trial . Patients receive phenylbutyrate central venous catheter 28 day cycle . The first several day drug administration inpatient . Cycles may repeat tumor progression dose limit toxicity ( DLT ) . There breaks cycle . Once minimum 3 patient complete least 4 week therapy without DLT , new patient enter next dose level .</brief_summary>
	<brief_title>Phase I Pharmacokinetic Trial Phenylbutyrate Given Continuous Infusion Pediatric Patients With Refractory Malignancy</brief_title>
	<detailed_description>Phenylbutyrate aromatic fatty acid convert phenylacetate vivo mitochondrial beta-oxidation phenylacetate . Preclinical study show continuous exposure phenylacetate phenylbutyrate induce tumor cytostasis differentiation wide variety cell line include malignant glioma neuroblastoma . However , phenylbutyrate show potent differentiate agent phenylacetate variety tumor cell line . In addition , phenylbutyrate appear molecular activity distinct phenylacetate . The objective trial determine maximum tolerate dose toxicity phenylbutyrate administer continuous intravenous infusion 28 day . In addition , pharmacokinetics phenylbutyrate metabolite , phenylacetate , study use model-dependent model-independent parameter .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<criteria>Disease Characteristics : Histologically proven cancer refractory standard therapy . Patients neurofibromatosis progressive inoperable plexiform neurofibromas potential cause significant morbidity eligible . Patients brainstem gliomas histology may histology requirement waive . Patients without prior therapy eligible disease available standard therapy . Patients evidence bone marrow involvement tumor , history either bone marrow transplantation extensive radiotherapy eligible , inevaluable hematologic toxicity . Patients great grade 2 neurocortical toxicity exclude . PRIOR/CONCURRENT THERAPY : Biologic Therapy : No concurrent hematopoietic growth factor . Chemotherapy : No chemotherapy within 3 week study . No nitrosoursea within 6 week study . No concurrent chemotherapy allow . Must stable decrease dose dexamethasone within 2 week study . Endocrine Therapy : Not specify . Radiotherapy : No radiotherapy within 6 week study . Surgery : Not specify . Other : Patient must recover toxic effect prior therapy . Concurrent antibiotic therapy appropriate . Patient Characteristics : Age : 2 21 . Performance Status : ECOG 02 . Life Expectancy : At least 8 week . Hematopoietic ( hematologic requirement apply patient histologically confirm bone marrow involvement history either bone marrow transplantation extensive radiotherapy ; patient inevaluable hematologic toxicity ) : Absolute granulocyte count ( AGC ) least 1500/mm3 . Platelet count least 100,000/mm3 . Hemoglobin least 8 g/dL . Hepatic : Bilirubin great 2 mg/Dl . SGPT less 2 time normal . Renal : Creatinine great 1.5 mg/Dl OR Creatinine clearance least 60 Ml/min/square meter . Other : No systemic illness . Not pregnant nursing . No amino acidurias organic acidemia .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1999</verification_date>
	<keyword>Brain Tumors</keyword>
	<keyword>Differentiation</keyword>
	<keyword>Maximally Tolerated Dose</keyword>
	<keyword>Neuroblastoma</keyword>
	<keyword>Phenylacetate</keyword>
</DOC>